Clinical trial
A Multi-center, Double-blind, Placebo-controlled Phase 4 Study in Patients With Pulmonary Arterial Hypertension to Assess the Effect of Selexipag on Daily Life Physical Activity and Patient's Self-reported Symptoms and Their Impacts
NCT03078907 is registered in ClinicalTrials.gov with Actelion as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center, Double-blind, Placebo-controlled Phase 4 Study in Patients With Pulmonary Arterial Hypertension to Assess the Effect of Selexipag on Daily Life Physical Activity and Patient's Self-reported Symptoms and Their Impacts
- Lead sponsor
- Actelion
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- November 8, 2017
- Completion date
- February 10, 2020
- Enrollment
- 108 (actual)
- Sites
- 39
Conditions
As the registry lists them; a condition with its own page is linked.